News: UNITY begins phase I trials for DME treatment

Biotechnology company UNITY has initiated doses for Phase I clinical trial of potential drug candidate for patients with diabetic macular edema (DME.) UNITY works to develop treatments focused on improving quality of life in aging patients, and increasing the health-span by slowing or reversing diseases of aging. DME is one such disease, and is a complication of diabetic retinopathy that occurs when too much blood sugar causes damage to blood vessels in the retina, sometimes leading to vision loss.


The UNITY study is in its first phase and is beginning human medical trials with open-label, single-ascending dose research to test for the safety and effectiveness of the drug in patients with advanced DME. The drug was developed from a Bcl-xL inhibiting compound, and works by impacting senescent cells. In preclinical tests, the drug (called UNX1325) was reported to reduce vascular leakage and improve retinal function.


UNITY is based out of San Francisco, CA and maintains a licensing agreement with Ascentage Pharma, primarily headquartered in Suzhou China, authorizing them to screen Ascentage’s compound library for anti-aging disease treatments. Dosing the first patient with UBX1325 will result in a significant payment milestone for Ascentage.


On their collaboration with UNITY, Ascentage CEO Dr Dajun Yang said: “We are confident that our collaboration in developing therapies for age-related diseases will bring fresh hope to patients around the world.”


Stay Up to Date on Clinical Trials

Citrus is a fully integrated recruitment and retention software that fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.

Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.

Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.

With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.

Still a little unsure? Check out what our customers have to say about us here.

And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.


Citruslabs

Copyright © 2021

All rights reserved

MindMate Inc.

Company

Product

Support

  • LinkedIn
  • Twitter
  • Instagram

1639 11th Street, Suite B-208, Santa Monica, CA 90404